Author(s): Sharif-Askari Z; Atoui K; El Zein W; Rizk M; Sharif Askari E;

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the gradual destruction of cognitive and behavioral functions. Despite the continuous research efforts, there is still no cure for this disease. In recent years, researchers have investigated Porphyromonas gingivalis (P. gingivalis) as a potential cause of AD. P. gingivalis-lipo ...

Article GUID: 41940869

Author(s): Gu Y; Hsu CL; Boa Sorte Silva NC; Tam RC; Alkeridy WA; Lam K; Liu-Ambrose T;

Background: Subcortical ischemic vascular cognitive impairment (SIVCI) is characterized by white matter hyperintensities (WMH) that contribute to executive dysfunction and increased risk of Alzheimer's disease. Cognitive reserve (CR) is the brain's ability to maintain cognitive performance despite pathology. Resting-state functional connectivity ( ...

Article GUID: 41929984

Author(s): Seixas-Lima B; Rosa-Neto P; Phillips NA; Borrie M; Roncero CT; Lahiri D; Dori D; Eintracht S; Chertkow H;

Background"Inflammaging" describes chronic low-grade inflammation observed in aging individuals. It may play a major role in neurodegeneration.ObjectiveTo assess blood inflammatory markers in older adults. We hypothesized that elevated inflammation would be found in some cognitively nor ...

Article GUID: 41358624

Author(s): Jobin B; Phillips NA; Frasnelli J; Boller B;

BackgroundOlfactory identification decline is a known early marker of Alzheimer's disease and is already present at the mild cognitive impairment (MCI) stage. While being linked with episodic memory, its predictive value for cognitive performance and distinguishing between clinical stages remains unclear.ObjectiveThis study examined (1) the predictive ...

Article GUID: 40944318

Author(s): Hosseininasabnajar F; Kakinami L;

Loss of brain tissues and cognitive abilities are natural processes of aging, but longitudinal studies are limited. We explored the longitudinal association between global and regional brain measures with cognitive abilities among individuals with normal cognitive status, mild cognitive impairment, and Alzheimer's Disease, including those with stable ...

Article GUID: 40739300

Author(s): Parent O; Alasmar Z; Osborne S; Bussy A; Costantino M; Fouquet JP; Quesada D; Pastor-Bernier A; Fajardo-Valdez A; Pichet-Binette A; McQuarrie A; Maranzano J; Devenyi GA; Steele CJ; Villeneuve S; ; Dadar M; Chakravarty MM;

White matter hyperintensities (WMHs) are neuroimaging markers widely interpreted as caused by cerebral small vessel disease, yet emerging evidence suggests that a subset may have a neurodegenerative etiology. Current imaging methods have lacked the specificity to disentangle biological processes ...

Article GUID: 40585093

Author(s): Campbell JR; Russell WA; Wagner CE; Manuel DG; Anipindi V; Baral P; Evans TG; Hankins CA; Sander B;

The Government of Canada, through the COVID-19 Immunity Task Force (CITF), supported over 100 serosurveillance studies during the COVID-19 pandemic, building and strengthening the technical infrastructure necessary for a national serosurveillance network. The value of such a network extends beyon ...

Article GUID: 40588636

Author(s): Sanami S; Intzandt B; Huck J; Villeneuve S; Iturria-Medina Y; Gauthier CJ; Prevent-Ad Research Group None;

Alzheimer's disease (AD) is a complex disease that involves complex interactions between protein biomarkers such as amyloid beta (Aß) and tau, neurodegeneration, cerebrovascular health and inflammation. However, how these factors interact, especially in the early phases of disease development ...

Article GUID: 40347524

Author(s): Pellerin S; Houzé B; Bedetti C; Phillips N; Brambati SM;

BackgroundMild cognitive impairment (MCI), a prodromal stage of Alzheimer's disease (AD) for many individuals, is accompanied by widespread connected speech (CS) changes (e.g., shorter CS samples, mention of fewer semantic content units, lower syntactic complexity). Nevertheless, findings on CS in MCI are heterogeneous. This heterogeneity, combined wi ...

Article GUID: 40232260

Author(s): Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Coll ...

Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To inform Canadian decisions on approval and use of these drugs, the Canadian Con ...

Article GUID: 39893139

Author(s): Páez A; Gillman SO; Dogaheh SB; Carnes A; Dakterzada F; Barbé F; Dang-Vu TT; Ripoll GP;

Introduction: Changes in sleep physiology can predate cognitive symptoms by decades in persons with Alzheimer's disease (AD), but it remains unclear which sleep characteristics predict cognitive and neurodegenerative changes after AD onset. Methods: Using data from a prospective cohort of mild to moderate AD (n = 60), we analyzed non-rapid eye moveme ...

Article GUID: 39878233